Skip to Content

John F. de Groot, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Neuro-Oncology Fellowship Program, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1998 The University of Texas Medical Branch at Galveston, Galveston, TX, MD, Honors, Medicine
1992 Stanford University, Stanford, CA, BA, Human Biology

Postgraduate Training

7/2002-6/2004 Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1999-6/2002 Clinical Residency, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
7/1998-6/1999 Clinical Internship, Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD

Board Certifications

7/2013 United Council for Neurologic Subspecialties (UCNS) - Neuro-Oncology
4/2002 American Board of Psychiatry and Neurology, Recertification Date: 2/2013


Academic Appointments

Assistant Professor, Department of Neuro-Oncology, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2004-8/2010

Administrative Appointments/Responsibilities

Director, Clinical Research, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2013-7/2015

Selected Publications

Peer-Reviewed Original Research Articles

1. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 17(8):1051-63, 8/2015. e-Pub 5/2015. PMCID: PMC4490873.
2. Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci 353(1-2):92-7, 6/2015. e-Pub 4/2015. PMID: 25934342.
3. Martinez-Ledesma E, de Groot JF, Verhaak RG. Seek and destroy: relating cancer drivers to therapies. Cancer Cell 27(3):319-21, 3/2015. PMID: 25759016.
4. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20(22):5612-9, 11/2014. PMCID: PMC4234180.
5. Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. e-Pub 11/2014. PMID: 25388940.
6. Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol 16(9):1289-94, 9/2014. e-Pub 3/2014. PMCID: PMC4136891.
7. Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep 14(5):443, 5/2014. PMID: 24652451.
8. Chen SE, Choi SS, Rogers JE, Lei X, de Groot JF. Isotretinoin Maintenance Therapy for Glioblastoma: A Retrospective Review. J Oncol Pharm Pract 20(2):112-9, 4/2014. e-Pub 5/2013. PMID: 23676507.
9. de Groot JF, Mandel JJ. Update on Anti-angiogenic Treatment for Malignant Gliomas. Curr Oncol Rep 16(4):380, 4/2014. PMID: 24510742.
10. Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol 16(3):409-13, 3/2014. e-Pub 12/2013. PMCID: PMC3922509.
11. Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res 20(1):187-98, 1/1/2014. e-Pub 11/15/2013. PMID: 24240114.
12. Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol 16(2):303-9, 1/2014. e-Pub 12/4/2013. PMCID: PMC3895378.
13. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 9(3):e91216, 2014. e-Pub 3/2014. PMCID: PMC3948818.
14. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition. Clin Cancer Res 19(16):4392-403, 8/2013. e-Pub 6/2013. PMID: 23804423.
15. Shonka N, Piao Y, Gilbert M, Yung WKA, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot JF. Cytokines associated with toxicity in treatment of recurrent Glioblastoma with Aflibercept. Target Oncology 8(2):117-125, 6/2013. e-Pub 1/2013. PMID: 23345034.
16. Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 86(2):277-84, 6/2013. e-Pub 2/2013. PMCID: PMC3954470.
17. Kamiya-Matsuoka C, Garciarena P, Hesham MA, Tremont I, de Groot JF. B Lymphoblastic Leukemia/Lymphoma Presenting As Seventh Cranial Nerve Palsy. Neurology, 2013.
18. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma Resistance to Anti-VEGF Therapy is Associated with Myeloid Cell Infiltration, Stem Cell Accumulation, and a Mesenchymal Phenotype. Neuro Oncol 14(11):1379-1392, 11/2012. e-Pub 9/10/2012. PMCID: PMC3480262.
19. Theeler BJ, Yung WK, Fuller GN, de Groot JF. Moving Toward Molecular Classification of Diffuse Gliomas in Adults. Neurology 79(18):1917-1926, 10/2012. PMCID: PMC3525311.
20. Walker GV, Li J, Mahajan A, McAleer MF, de Groot JF, Azeem SS, Brown PD. Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: A population-based analysis. Cancer 118(18):4538-44, 9/15/2012. e-Pub 2/22/2012. PMID: 22359097.
21. de Groot JF, Liang J, Kong LK, Wei J, Piao Y, Fuller G, Qiao W, Hemberger AB. Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator Transcription 3 Pathway in Glioblastoma. Oncotarget 9(3):1036-48, 9/2012. PMID: 23013619.
22. Grossman KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, de Groot JF, Aiken RD, Olsen JJ, Evans BA, Jensen RL. Phase I Trial of Verubulin (MPC-6827) plus carboplatin in Patients with Relapsed Glioblastoma Multiforme. Journal of Neuro Oncology. e-Pub 8/2012. PMID: 22932984.
23. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WKA. A Phase I Factorial Design Study of Dose-Dense Temozolomide Alone and in Combination with Thalidomide, Isotretinoin, and/or Celecoib as Postchemoradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Neuro-Oncology 12(11). e-Pub 8/2010. PMCID: PMC3098026.
24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, de Groot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 28(11):1963-72, 4/2010. e-Pub 3/2010. PMID: 20231676.
25. Ahluwalia MS, de Groot J, Liu W, Gladson CL. Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Letters 298(2):139-49, 2010. PMID: 20947248.
26. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy. Clin Cancer Res 15(14):4589-99, 7/2009. PMID: 19567589.
27. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via (beta) 1 integrin-dependent adhesion to the extracellular matrix. Neuro-Oncology 11(3):260-73, 6/2009. PMCID: PMC2718970.
28. Milano V, Piao Y, Lafortune T, de Groot J. Desatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Molecular Cancer Therapy 8(2):394-406, 2/2009. PMID: 19190119.
29. Gonzales J, de Groot J. Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Therapy 8(11):1767-1779, 11/2008. PMID: 18983237.
30. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neuro-Oncology 90(1):89-97, 10/2008. PMID: 18581057.
31. de Groot J, Yung, WKA. Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas. Cancer J 14(5):279-285, Sep-Oct, 2008. PMID: 18836331.
32. Gomez-Manzano C, Holash J, Fueyo J, Xu Jing, Conrad, CA, Aldape KD, de Groot JF, Bekele N, Yung WKA. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology 10(6):940-945, 2008. PMID: 18708344.
33. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65(5):1934-40, 2005. PMID: 15753393.

Book Chapters

1. de Groot JF, Yung, WK. Small Molecule Based Therapies. In Neuro-Oncology. In: The Essentials 2nd. Edition, 2nd. Ed(s) Bernstein & M. Berger. Thieme Publishers: New York, NY, 234-241, 2008.

Grant & Contract Support

Title: SPORE for Brain Tumors: Animal Core (Core E)
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Fredrick Lang, Jr
Duration: 9/1/2013 - 8/31/2018
Title: Evaluation of Novartis oncology compounds to validate specific targeted therapies in glioblastoma with unique subtype and molecular profiles
Funding Source: Novartis
Role: Principal Investigator
Duration: 6/1/2013 - 12/31/2015
Title: Molecular Predictors of Response to Targeted Therapy in Glioblastoma: Preclinical Validation of Eli Lilly Compounds Targeting CDK4/6, SHH, FGFR, cMET, and p38-MAPK
Funding Source: Eli Lilly
Role: Principal Investigator
Duration: 10/1/2012 - 6/25/2015
Title: Ivy CTC Virtual Tissue Bank for Malignant Glioma Patients
Funding Source: Ivy Foundation Early Phase Clinical Trials Consortium
Role: Principal Investigator-MDACC
Principal Investigator: Prado
Duration: 7/1/2012 - 11/30/2016
Title: Preclinical Validation of Targeting P70S6K/AKT with MSC3318
Funding Source: EMD Serono
Role: Principal Investigator
Duration: 7/1/2012 - 10/31/2015
Title: Evaluation of XL765 for the Prevention of Glioblastoma Resistance to Bevacizumab Therapy
Funding Source: Sanofi-Aventis
Role: Principal Investigator
Duration: 9/1/2011 - 12/31/2014
Title: Preclinical Validation of Targeting the JAK/STAT Pathway in Glioma with AZD1480
Funding Source: AstraZeneca
Role: Investigator
Duration: 9/1/2011 - 9/11/2014
Title: SPORE DRP- Targeting the JAK2/STAT-3 Pathway in Glioma to Overcome Resistance to Antiangiogenic Therapy
Funding Source: NIH/NCI
Role: Investigator
Duration: 9/1/2011 - 8/31/2013
Title: Modulation of Resistance to Antiangiogenic Therapy: A Clinical Trial with Correlative Studies
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/16/2010 - 6/30/2014
Title: Preclinical Validation of Targeting Macrophage CSF-1R in Glioblastoma
Funding Source: AstraZeneca Research Collaboration Alliance
Role: Principal Investigator
Duration: 9/2009 - 7/31/2013
Title: Predictors of Glioblastoma Response to VEGF Trap
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2011
Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 7/1/2008 - 6/30/2010
Title: The Role of AMPA Receptors in Glioma Proliferation and Invasion
Funding Source: UTMDACC Institutional Research Grant-IRG
Role: Principal Investigator
Duration: 2/1/2008 - 1/31/2010
Title: The effect of CT-322 on glioma biology and growth in an in vivo glioma stem cell model
Funding Source: Adnexus
Role: Principal Investigator
Duration: 1/2008 - 1/31/2011
Title: Correlative Markers of Glioblastoma Response to VEGF Trap
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/2007 - 5/31/2010
Title: Deciphering Synergistic Combinatorial Targets in Glioma
Funding Source: NIH/NCI/NINDS
Role: Co-Investigator
Principal Investigator: W.K. Alfred Yung
Duration: 9/2006 - 6/30/2012
Title: ImaRx Therapeutics Investigator Initiated Study "Enhancing drug delivery using ultrasound plus nanobubbles"
Funding Source: ImaRX
Role: Principal Investigator
Duration: 6/2005 - 7/2006
Title: Glutamate excitotoxicity, cystine and glioma growth
Funding Source: American Brain Tumor Association (ABTA) - Basic Research Fellowship
Role: Investigator
Duration: 7/3/2003 - 6/5/2005
Title: Adaptive selection design with molecular subset analysis: A Bayesian paradigm to optimize treatment success for patients with glioblastoma, Submitted
Funding Source: The Ben and Catherine Ivy Foundation
Role: Co-Investigator

Last updated: 8/31/2015